Retatrutide adds GIP and glucagon receptor agonism on top of GLP-1. What does the glucagon component actually do metabolically, what does the Phase 2 data show, and which patients does the third mechanism change the equation for?
Read Article →GLP-1 vs dual GIP/GLP-1 agonism — what it means for candidate selection, trial data, tolerability, and compounded context.
Read Article →Seven questions every physician should be able to answer before committing to a supplier.
Read Article →A Certificate of Analysis is only useful if you know what it's telling you. Every field explained, what to verify, and the red flags that indicate a COA isn't worth the paper it's printed on.
Read Article →Our manufacturing partner operates under USP-797, the federal standard for sterile compounded injectables. What it means, why it matters to you.
Read Article →The glucagon receptor adds thermogenesis and direct hepatic effects that pure GLP-1 agonism cannot match. Phase 2 data, clinical differentiators, and a candidate selection framework.
Read Article →Both compounds share GIP/GLP-1 dual agonism. The glucagon receptor is the differentiator — what it adds mechanistically, what the Phase 2 data shows, and the specific clinical scenarios where it changes the decision.
Read Article →Cost structure, compound margin profiles, inventory velocity, and an honest look at where the financial model is strong and where the variables matter — by practice type.
Read Article →The eligible population in most practices is 3–5x larger than the intuitive estimate. Why documentation gaps and memory bias produce an undercount, and how a systematic EHR query closes it.
Read Article →